Collectively, these ligands, EGFR/EGFRvIII, AS1411, IL-13, RGD, chlorotoxin, and Angiopep-2, strengthen the potential of MSNs for multimodal GBM strategies, including targeted drug delivery alongside imaging, photodynamic therapy, or radiosensitization. This evidence concerns the gene EGFR and glioblastoma.